PHILADELPHIA — Rite Aid and Google Cloud are entering a multi-year technology partnership to help Rite Aid realize its vision of a modern pharmacy, the companies said on Tuesday. Google Cloud technologies will provide Rite Aid with better insights, increased agility and improved customer experiences, the companies added. Modernized applications for personalized digital experiences will
ARLINGTON, Va. — Join NACDS president & CEO Steve Anderson and national political analyst Charlie Cook in an exciting virtual NACDS RxIMPACT Votes event to learn more about the 2022 elections and what that might mean for the future of pharmacy. Register to attend this virtual event taking place at 1:00pm ET on September
WEST DES MOINES, Iowa —Hy-Vee Inc. announced this week that all Hy-Vee Pharmacy locations across its eight-state region now offer test-to-treat COVID-19 services using the COVID-19 antiviral, Paxlovid, to help treat mild-to-moderate cases of COVID-19 in certain patients who are at high risk for progression to severe COVID-19. Earlier this month, the FDA authorized state-licensed
WASHINGTON – Pharmacy groups praised the U.S. Food and Drug Administration on the revised Emergency Use Authorization (EUA) for Paxlovid (nirmatrelvir and ritonavir), to authorize state-licensed pharmacists to prescribe Paxlovid to eligible patients, with certain limitations to ensure appropriate patient assessment and prescribing of Paxlovid. “The FDA’s action is an extremely important revision for patient access
ARLINGTON, Va. — On Tuesday, the National Association of Chain Drug Stores and 93 other patient, public health, and state and national pharmacy groups, signed a letter to the Biden Administration urging “formal clarification from the U.S. Department of Health and Human Services (HHS) on potential expiration of pharmacy personnel flexibilities granted during the pandemic.” READ LETTER Throughout the COVID-19 pandemic,
ARLINGTON, Va. — NACDS on Monday expressed appreciation for a new federal rule that will help to reduce seniors’ out-of-pocket prescription drug costs by improving transparency of exorbitant direct and indirect remuneration (DIR) fees imposed by payers on pharmacies. NACDS insists that comprehensive DIR fee reform now depends on further legislative and regulatory action to